Trifecta of Willingness to Pay for Rare Diseases: Payers, HCPs, and Society

Speaker(s)

Sumeet Bakshi, MBBS, MBA, Lifescience Dynamics, London, UK, Andrew Olaye, MSc, PhD, Orchard Therapeutics, London, UK, Domenico Moro, PhD, University of Birmingham, London, UK and Thomas J Butt, PhD, BioMarin Europe Ltd, London, UK

Conventional cost-effectiveness analysis may be inappropriate to assess therapies for rare and ultra-rare diseases and further counteract incentives that aim to foster development of such therapies. In this session we will be discussing and exploring alternative evaluation methods that could more appropriately assess the value of interventions for rare and ultra-rare diseases.

Sponsored by Lifescience Dynamics

Code

224

Topic

Health Technology Assessment